We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies.
Location: United States
Employees: 51-200
Total raised: $324M
Founded date: 2014
Investors 7
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| 14.07.2025 | Terra Magn... | terramagnu... |
| - | Takeda Ven... | takeda.com |
| - | LG Technol... | lgtechvent... |
| - | JVC Invest... | jvcmanagem... |
| 01.03.2023 | Solasta Ve... | solasta-ve... |
| - | SR One | srone.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 08.02.2022 | - | $124M | - |
| 15.04.2021 | Series C | $115M | - |
| 04.10.2019 | Series B | $85M | - |
Mentions in press and media 23
| Date | Title | Description |
| 07.04.2026 | Gilead приобретает немецкого производителя противораковых препаратов Tubulis за $5 млрд | Во вторник американская фармкомпания Gilead объявила о планах приобретения частной немецкой компании Tubulis GmbH за сумму до $5 млрд. Сделка направлена на расширение портфеля компании за счет перспективного класса экспериментальных противо... |
| 24.03.2026 | Gilead покупает Ouro Medicines более чем за $2 млрд и усиливает ставку на иммунологию | По условиям сделки Gilead выплатит инвесторам Ouro $1,68 млрд авансом наличными, а также еще до $500 млн в случае достижения определенных этапов разработки препарата. Ключевым активом в этой покупке является экспериментальный препарат OM336... |
| 27.02.2026 | Gilead Dominates Cell Therapy: $7.8 Billion Arcellx Acquisition Seals Future | Gilead Sciences acquired Arcellx for up to $7.8 billion. This landmark acquisition secures full control of anito-cel, a potentially transformative BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Anito-cel await... |
| 24.02.2026 | Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy | - |
| 23.02.2026 | Фармгигант из США Gilead заплатит до $7,8 млрд за разработчика CAR-T - терапии Arcellx | Gilead покупает разработчика противораковых препаратов Arcellx за сумму до $7,8 млрд. Gilead согласилась приобрести Arcellx в сделке стоимостью $7,8 млрд, поскольку фармкомпания стремится добавить в свой портфель CAR-T-клеточную терапию про... |
| 23.02.2026 | Gilead Sciences Acquires Arcellx, for $7.8 Billion | Gilead Sciences, Inc. (Nasdaq: GILD), a Foster City, California-based provider of biopharmaceutical medicines for life-threatening diseases, acquired Arcellxi (NASDAQ:ACLX) , a Redwood City, California-based provider of innovative immunothe... |
| 23.02.2026 | Maazah Raises $2M in Seed Funding | Maazah, a Minneapolis, MN-based based food brand developing dips and sauces, raised $2M Seed funding. Backers were not disclosed. The company intends to use the funds to support nationwide retail growth and expanded distribution. Founded by... |
| 23.02.2026 | Stocks making the biggest moves premarket: Arcellx, Novo Nordisk, Domino’s Pizza and more | - |
| 29.01.2026 | Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026" | HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-dep... |
| 12.01.2026 | Vibrant Therapeutics: $61 Million Closed And Han Lee Named As Co-CEO | Vibrant Therapeutics, a clinical-stage biotech developing “logic-gated” therapeutics designed to activate selectively in diseased tissue, announced it has raised $61 million in new financing and appointed Han Lee, Ph.D. as co-chief executiv... |
Show more